Cargando…

A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients

BACKGROUND: The prevalence and types of fibroblast growth factor receptor (FGFR) mutations vary significantly among different ethnic groups. The optimal application of FGFR inhibitors depends on these variations being comprehensively understood. However, such an analysis has yet to be conducted in C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Yi, Li, Gao, Zhu, Wei, He, Qiuyan, Liu, Yongchang, Chen, Xianshan, Liu, Juan, Lin, Jing, Han-Zhang, Han, Yang, Zheng, Lizaso, Analyn, Xiang, Jianxing, Mao, Xinru, Liu, Hao, Gao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661893/ https://www.ncbi.nlm.nih.gov/pubmed/33209870 http://dx.doi.org/10.21037/atm-20-5118

Ejemplares similares

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
por: Zhou, Yuling, et al.
Publicado: (2020)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
por: Lin, Quan, et al.
Publicado: (2019)

Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer
por: Xiao, Weikai, et al.
Publicado: (2021)

A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients
por: Gao, Guanghui, et al.
Publicado: (2021)

Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
por: Hu, Xingsheng, et al.
Publicado: (2019)

Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non‐small cell lung cancer patients
por: Ding, Ying, et al.
Publicado: (2019)

Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
por: Hu, Xingsheng, et al.
Publicado: (2020)

High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
por: Wu, Shibo, et al.
Publicado: (2020)

Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling
por: Guo, Zhihua, et al.
Publicado: (2019)

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
por: Liu, Lian-Fang, et al.
Publicado: (2022)

Revealing the roles of TLR7, a nucleic acid sensor for COVID-19 in pan-cancer
por: Huang, Zhijian, et al.
Publicado: (2023)

Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients
por: Tao, Zhonghua, et al.
Publicado: (2020)

Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment
por: Li, Juanni, et al.
Publicado: (2021)

An integrated pan‐cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity
por: Liu, Jian‐Nan, et al.
Publicado: (2020)

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
por: Zhang, Yongchang, et al.
Publicado: (2021)

Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications
por: Zhou, Zhiyang, et al.
Publicado: (2021)

A comprehensive pan-cancer analysis of necroptosis molecules in four gynecologic cancers
por: Zheng, Jianfeng, et al.
Publicado: (2022)

Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review
por: Xie, Tong, et al.
Publicado: (2021)

Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment
por: Luo, Han, et al.
Publicado: (2022)

Comprehensive analysis of REST corepressors (RCORs) in pan-cancer
por: Zheng, Rong, et al.
Publicado: (2023)

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
por: Ma, Shenglin, et al.
Publicado: (2021)

Comprehensive analysis of DTYMK in pan-cancer and verification in lung adenocarcinoma
por: Zhang, Yue, et al.
Publicado: (2022)

Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
por: Liu, Jian-Nan, et al.
Publicado: (2020)

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
por: Zhang, Yongchang, et al.
Publicado: (2021)

Clinical Characteristics and Molecular Patterns of RET-Rearranged Lung Cancer in Chinese Patients
por: Zhang, Kai, et al.
Publicado: (2019)

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics
por: Xiao, Weikai, et al.
Publicado: (2021)

A Comprehensive Analysis of METTL1 to Immunity and Stemness in Pan-Cancer
por: Gao, Zijie, et al.
Publicado: (2022)

Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients
por: Liu, Yixiao, et al.
Publicado: (2023)

The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients
por: Cao, Liming, et al.
Publicado: (2018)

Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis
por: Liu, Haijing, et al.
Publicado: (2020)

A Comprehensive Analysis of the Prognostic, Immunological and Diagnostic Role of CCNF in Pan-cancer
por: Gao, Xiaofeng, et al.
Publicado: (2023)

LRH1 Acts as an Oncogenic Driver in Human Osteosarcoma and Pan-Cancer
por: Song, Yang, et al.
Publicado: (2021)

The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report
por: Liu, Bin, et al.
Publicado: (2021)

Comprehensive Analysis of the Aberrance and Functional Significance of Ferroptosis in Gastric Cancer
por: Xiao, Jun, et al.
Publicado: (2022)

Comprehensive landscape and interference of clonal haematopoiesis mutations for liquid biopsy: A Chinese pan‐cancer cohort
por: Xu, Enwu, et al.
Publicado: (2021)

Machine Learning-Based Comparative Analysis of Pan-Cancer and Pan-Normal Tissues Identifies Pan-Cancer Tissue-Enriched circRNAs Related to Cancer Mutations as Potential Exosomal Biomarkers
por: Wang, Xuezhu, et al.
Publicado: (2021)

Aberrant PRDM9 expression impacts the pan-cancer genomic landscape
por: Houle, Armande Ang, et al.
Publicado: (2018)

Pan-cancer predictions of transcription factors mediating aberrant DNA methylation
por: Detilleux, Dylane, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b3iebtpth7e4g8kiriqn0a3pfi